High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: Phase I trial in combination with vinblastine

Journal of the National Cancer Institute

Volumn 84, Issue 23, 1992, Pages 1811-1816

  Trump, Donald L ^a   Smith, David C ^a   Ellis, Peter G ^a   Rogers, Miriam P ^a   Schold, S Clifford ^a   Winer, Eric P ^a   Panella, Timothy J ^a   Jordan, V Craig ^b   Fine, Robert L ^a  

^a DUKE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NORTAMOXIFEN; TAMOXIFEN; VINBLASTINE;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; DRUG BLOOD LEVEL; DRUG INFUSION; DRUG MEGADOSE; DRUG MIXTURE; DRUG MONITORING; EPITHELIUM TUMOR; FEMALE; GRAND MAL SEIZURE; HUMAN; HYPERREFLEXIA; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; TREMOR; VERTIGO;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; HUMAN; INFUSIONS, INTRAVENOUS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGE; NEOPLASM PROTEINS; NEOPLASMS; P-GLYCOPROTEIN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; TAMOXIFEN; VINBLASTINE;

EID: 0026445750     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/84.23.1811     Document Type: Article

References (41)

1. Biedler JL, Riehm H: Cellular resistance to actinomycin D in Chinese hamster cells in vitro: Cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174-1184, 1970
2. Ling V, Thompson L: Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83:103-116, 1973
3. Bech-Hansen NT, Till JE, Ling V: Pleio-tropic phenotype of colchicine-resistant CHO cells: Cross resistance and collateral sensitivity. J Cell Physiol 88:23-31, 1976
4. Dano K: Active outward transport of daunomycin in Ehrlich ascites tumor cells. Biochim Biophys Acta 323:466-483, 1973
5. Kartner N, Riordan JR, Ling V: Cell surface P-glycoprotein associated with mul-tidrug resistance in mammalian cell lines. Science 221:1285-1288, 1983
6. Ueda K, Cardarelli C, Gottesman MM, et al: Expression of a full-length cDNA for the human MDR 1: Gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci U S A 84:3004-3008, 1987
7. Dalton WS, Grogan TM, Meltzer PS, et al: Drug-resistance in multiple myeloma and non-Hodgkin’s lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 7:415-424, 1989
8. Fojo AT, Shen D-W, Mickley LA, et al: Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene. J Clin Oncol 5:1922-1927, 1987
9. Salmon SE, Grogan TM, Miller T, et al: Prediction of doxorubicin resistance in vitro in myeloma, lymphoma, and breast cancer by P-glycoprotein staining. J Natl Cancer Inst 81:696-701, 1989
10. Goldstein LJ, Galski H, Fojo A, et al: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989
11. Bell DR, Gerlach JH, Kartner N, et al: Detection of P-glycoprotein in ovarian cancer: A molecular marker associated with multidrug resistance. J Clin Oncol 3:311-315, 1985
12. Chauffert B, Rey D, Coudert B, et al: Amiodarone is more efficient than verapamil in reversing resistance to an-thracyclines in tumour cells. Br J Cancer 56:119-122, 1987
13. Bellelli A, Camboni C, DeLuca G, et al: In vitro and in vivo enhancement of vincristine antitumor activity on B16 melanoma cells by calcium antagonist flunarizine. Oncology 44:17-23, 1987
14. Radel S, Bankusli I, Mayhew E, et al: The effects of verapamil and a tiapamil analogue, DMDP, on adriamycin-induced cytotoxicity in P388 adriamycin-resistant and -sensitive leukemia in vitro and in vivo. Cancer Chemother Pharmacol 21:25-30, 1988
15. Ozols RF, Cunnion RE, Klecker RW Jr, et al: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol 5:641-647, 1987
16. Tsuruo T, Iida H, Tsukagoshi S, et al: Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 41:1967-1972, 1981
17. Bellamy WT, Dalton WS, Kailey JM, et al: Verapamil reversal of doxorubicin resistance in multidrug-resistant human myeloma cells and association with drug accumulation and DNA damage. Cancer Res 48:6365-6370, 1988
18. Cornwell MM, Pastan I, Gottesman MM: Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262:2166-2170, 1987
19. Benson AB III, Trump DL, Koeller JM, et al: A phase I study of vinblastine and verapamil given by concurrent iv infusion. Cancer Treat Rep 69:795-799, 1985
20. Rogan AM, Hamilton TC, Young RC, et al: Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science 224:994-996, 1984
21. Pennock GD, Dalton WS, Roeske WR, et al: Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83:105-110, 1991
22. Ramu A, Glaubiger D, Fuks F: Reversal of acquired resistance to doxorubicin in P388 murine leukemia cells by tamoxifen and other triparanol analogues. Cancer Res 44:4392-4395, 1984
23. Berman E, Adams M, Duigou-Osterndorf R, et al: Effects of tamoxifen on cell lines displaying the multi-drug resistant phenotype. Blood 7:818-825, 1991
24. Cantwell B, Carmichael J, Millward M, et al: Intermittent high dose tamoxifen (HDT) with oral etoposide (EPO): Phase I and II clinical studies. Proc ASCO 8:65, 1989
25. Fine RL, Sachs CW, Albers M, et al: Tamoxifen potentiates the cytotoxicity of vinblastine by increasing intracellular drug accumulation. Proc Am Assoc Cancer Res 32:375, 1991
26. DeGregorio MW, Ford JM, Benz CC, et al: Toremifene: Pharmacologic and pharmacokinetic basis of reversing multidrug resistance. J Clin Oncol 7:1359-1364, 1989
27. Brown RR, Bain R, Jordan VC: Determination of tamoxifen and metabolites in human serum by high performance liquid chromatography with post-column fluorescence activation. J Chromatogr 272:351-358, 1983
28. Fabian C, Sternson L, Barnett M: Clinical pharmacology of tamoxifen in patients with breast cancer: Comparison of traditional and loading dose schedules. Cancer Treat Rep 64:765-773, 1980
29. Tormey DC, Simon RM, Lippman ME, et al: Evaluation of tamoxifen dose in advanced breast cancer: A progress report. Cancer Treat Rep 60:1451-1459, 1976
30. Melia WM, Johnson PJ, Williams R: Controlled clinical trial of doxorubicin and tamoxifen versus doxorubicin alone in hepatocellular carcinoma. Cancer Treat Rep 71:1213-1216, 1987
31. Slater LM, Sweet P, Stupecky M, et al: Cyclosporin A corrects daunorubicin resistance in Ehrlich ascites carcinoma. Br J Cancer 54:235-238, 1986
32. Salmon SE, Lehnert M, Grogan T, et al: Verapamil (V) and quinine (Q) chemo-sensitize myeloma cells to doxorubicin (DOX) and vincristine (VCR) in vitro and are capable of reversing clinical relapses in multiple myeloma (MM). Blood [Suppl] 74:197, 1989
33. Keilhauer C, Emling F, Raschack M, et al: The use of R-verapamil (R-VPM) is superior to racemic VPM in breaking multidrag resistance (MDR) of malignant cells. Proc Am Assoc Cancer Res 30:503, 1989
34. Samuels B, Ratain M, Mick R, et al: Phase I trial of multidrug resistance modulation with cyclosporin A. Proc Am Assoc Cancer Res 32:195, 1991
35. Gosland MP, Brophy NA, Duran GE, et al: Bilirubin: A physiological substrate for the multidrug transporter. Proc Am Assoc Cancer Res 32:426, 1991
36. Daniel P, Gaskell SJ, Bishop H, et al: Determination of tamoxifen and biologically active metabolites in human breast tumours and plasma. Eur J Cancer Clin Oncol 17:1183-1189, 1981
37. DeGregorio MW, Wilbur BJ, Coronado E, et al: Serum tamoxifen concentrations in the athymic nude mouse after three methods of administration. Cancer Chem-other Pharmacol 20:316-318, 1987
38. Keane TE, Rosner G, Walther PJ: Modulation of vinblastine [VB] cytotoxicity by dipyridamole [DP] versus tamoxifen [TAM]: An in vivo preclinical study by subrenal capsule assay [SRCA] of human renal carcinoma [HRCC]. Proc Am Assoc Cancer Res 31:376, 1990
39. O’Brian CA, Liskamp RM, Soloman DH, et al: Triphenylethylenes: A new class of protein kinase C inhibitors. JNCI 76:1243-1246, 1986
40. Greenberg DA, Carpenter CL, Messing RO: Calcium channel antagonist properties of antineoplastic antiestrogen. Tamoxifen in the PC12 neurosecretory cell line. Cancer Res 47:70-74, 1987
41. Thiebaut F, Tsuruo T, Hamada H, et al: Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84:7735-7738, 1987